<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec id="j_raon-2019-0006_s_008">
<h3>Background</h3>
<p>The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.</p>
</sec>
<sec id="j_raon-2019-0006_s_009">
<h3>Conclusions</h3>
<p>Though effective dose-escalation methods have been explored, including altered fractionation, adapting individualized increments for different patients, and adopting new technologies and new equipment such as new radiation therapy, no consensus has been achieved yet.</p></sec>
</abstract>

Background
The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.


Conclusions
Though effective dose-escalation methods have been explored, including altered fractionation, adapting individualized increments for different patients, and adopting new technologies and new equipment such as new radiation therapy, no consensus has been achieved yet.

A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Background
The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the...

A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer

Article Category: Review

Publié en ligne: 03 mars 2019

Pages: 6 - 14

Reçu: 31 août 2018

Accepté: 05 janv. 2019

DOI: https://doi.org/10.2478/raon-2019-0006

© 2019 Li Ma, Yu Men, Lingling Feng, Jingjing Kang, Xin Sun, Meng Yuan, Wei Jiang, Zhouguang Hui published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.